Clinical Trial Update: Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update for CTX001 (exagamglogene autotemcel) assessing a single dose in transfusion-dependent beta-thalassemia and severe sickle cell dis…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Beta-thalassemia
• Sickle Cell Disease

Drugs mentioned

• CTX001

Snippet

Sponsor: Vertex Pharmaceuticals Incorporated | Conditions: Beta-Thalassemia, Thalassemia | Phase 3 | Status: RECRUITING